Participants will learn how to translate theoretical information deriving from recently completed trials of new anticoagulants in atrial fibrillation and from the recently revised 2012 ESC Atrial Fibrillation Guidelines into clinical practice.
Two challenging cases of atrial fibrillation management will be presented. Interactive discussion with the audience will lead the participant to logically choose the best treatment options for the cases. Pros and Cons of the available choices will be discussed.
Raffaele de Caterina and Gregory Lip
Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association.
R. De Caterina also suggests:Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007;28:880-913.De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 2012;59:1413-25.Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thrombosis and haemostasis 2010;103:13-28.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903 Sophia Antipolis, FR
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved